SWHR Urges ICER to Use Progressive Modeling to Assess Endometriosis Treatments

SWHR submitted comments to the Institute for Clinical and Economic Review (ICER) in advance of ICER’s assessment of the comparative clinical effectiveness of new treatments for endometriosis. SWHR emphasized the importance of using progressive modeling techniques to properly assess the indirect costs associated with the stigma and societal burden of endometriosis. As a thought leader in eliminating imbalances in care for women, SWHR offered to be a resource during ICER’s analysis on endometriosis and any other chronic conditions affecting women.

The comments highlight that, on average, women do not receive an endometriosis diagnosis until 6.7 years after first experiencing symptoms or they are misdiagnosed. Stigma and lack of education around endometriosis can lead to delated diagnosis and inadequate or inappropriate treatment. In addition, endometriosis can be accompanied by co-morbid conditions such as depression, anxiety, autoimmune and endocrine disorders, and migraine. SWHR encouraged ICER to take into account these factors, which are often overlooked or difficult to study.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

SWHR submitted comments to the Institute for Clinical and Economic Review (ICER) in advance of ICER’s assessment of the comparative clinical effectiveness of new treatments for endometriosis. SWHR emphasized the importance of using progressive modeling techniques to properly assess the indirect costs associated with the stigma and societal burden of endometriosis. As a thought leader in eliminating imbalances in care for women, SWHR offered to be a resource during ICER’s analysis on endometriosis and any other chronic conditions affecting women.

The comments highlight that, on average, women do not receive an endometriosis diagnosis until 6.7 years after first experiencing symptoms or they are misdiagnosed. Stigma and lack of education around endometriosis can lead to delated diagnosis and inadequate or inappropriate treatment. In addition, endometriosis can be accompanied by co-morbid conditions such as depression, anxiety, autoimmune and endocrine disorders, and migraine. SWHR encouraged ICER to take into account these factors, which are often overlooked or difficult to study.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

SWHR’s ICER Engagement

Blog Post
SWHR Develops Principles to Ensure Health Care Value Assessments Work for Women
When a new health care innovation comes to market, how do patients, health care providers, and health care payers determine its value?
Policy Engagement
SWHR Recommendations on ICER’s 2020 Value Assessment Framework
SWHR provided recommendations to the Institute for Clinical and Economic Review (ICER) on proposed changes to its 2020 value assessment framework to ensure it supports optimal health outcomes for women.
Policy Engagement
SWHR’s Health Care Value Assessment Principles
SWHR conceived a set of principles to ensure health care value frameworks and assessments reflect factors relevant to women and their health.
Policy Engagement
SWHR Provides Input on ICER Value Assessment Framework
SWHR provided input to the Institute for Clinical and Economic Review (ICER) on the 2020 update to its value assessment framework.
Blog Post
Determining the Value of New Therapies: ICER Explores the Role of Real-World Evidence
Women won’t benefit from new therapies unless they can access them, and patient access to new innovations is based, in part, on value assessment.
Policy Engagement
SWHR Recommends ICER Delay Report on Endometriosis Treatments
SWHR provided comments to the Institute for Clinical and Economic Review (ICER) on its draft report assessing new endometriosis therapies.
Policy Engagement
SWHR Input on ICER Migraine Therapies Draft Report
SWHR commented on ICER's migraine therapies draft report, regarding the effectiveness and value of calcitonin gene-related peptide (CGRP) inhibitors.
Policy Engagement
SWHR Urges ICER to Consider Disease Burden When Assessing Migraine Drugs
SWHR urged the Institute for Clinical and Economic Review (ICER) to incorporate the significant burden of migraine into its assessment of the effectiveness and value of drugs for migraine.